JAK2 and ovarian carcinoma: Furthermore, SENP1-mediated deSUMOylation and the activation of janus kinase 2 (JAK2) promotes platinum resistance in ovarian cancer, which can be overcome by pharmacological inhibition of SENP1 that sensitizes cancer cells to cisplatin [305].